Search research articles
Contact Us
Filters
Showing results (151-160 of 168) with videos related to
Page
of 17
Sort By:
Proceedings (Baylor University. Medical Center)
|
October 29, 2019
Selection of abstracts from Baylor Scott & White Health Central Texas Scholars Day
Angela D Rutherford, Wendy A Hegefeld, Hania W Janek, et al.
The American Journal of Cardiology
|
February 8, 2006
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation
Rupak Mukherjee, Amanda R Herron, Abigail S Lowry, et al.
American Journal of Physiology. Cell Physiology
|
August 3, 2007
Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy
Laura S Spruill, Abigail S Lowry, Robert E Stroud, et al.
Circulation
|
September 17, 2003
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling
William M Yarbrough, Rupak Mukherjee, G Patricia Escobar, et al.
Circulation
|
February 5, 2003
Myocardial infarct expansion and matrix metalloproteinase inhibition
Rupak Mukherjee, Theresa A Brinsa, Kathryn B Dowdy, et al.
Circulation
|
May 29, 2003
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling
Eric M Wilson, Sina L Moainie, Julia M Baskin, et al.
Circulation
|
September 1, 2005
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction
Aaron S Blom, Rupak Mukherjee, James J Pilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector Rodriguez, et al.
Vaccine
|
February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
Oyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccines
|
February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
Juleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 168) with videos related to
Sort By:
Page
of 17
Proceedings (Baylor University. Medical Center)
|
October 29, 2019
Selection of abstracts from Baylor Scott & White Health Central Texas Scholars Day
Angela D Rutherford, Wendy A Hegefeld, Hania W Janek, et al.
The American Journal of Cardiology
|
February 8, 2006
Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation
Rupak Mukherjee, Amanda R Herron, Abigail S Lowry, et al.
American Journal of Physiology. Cell Physiology
|
August 3, 2007
Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy
Laura S Spruill, Abigail S Lowry, Robert E Stroud, et al.
Circulation
|
September 17, 2003
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling
William M Yarbrough, Rupak Mukherjee, G Patricia Escobar, et al.
Circulation
|
February 5, 2003
Myocardial infarct expansion and matrix metalloproteinase inhibition
Rupak Mukherjee, Theresa A Brinsa, Kathryn B Dowdy, et al.
Circulation
|
May 29, 2003
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling
Eric M Wilson, Sina L Moainie, Julia M Baskin, et al.
Circulation
|
September 1, 2005
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction
Aaron S Blom, Rupak Mukherjee, James J Pilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 28, 2023
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
Lisa Usdan, Sohil Patel, Hector Rodriguez, et al.
Vaccine
|
February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
Oyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccines
|
February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
Juleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Page
of 17